China-based Edding Pharma is gearing up for its fifth attempt to hold an initial public offering (IPO) on the Hong Kong Stock Exchange. The company reported revenues of RMB 2.074 billion (USD 289 million) last year, with net profits reaching RMB 306.3 million (USD 42.67 million), primarily from a portfolio of in-licensed products.
Edding’s Business Model and Market Focus
First established in 2001, Edding has adopted a business model that emphasizes in-licensing and business development (BD) to build its product portfolio. The company exclusively acquires molecules from multinational corporations (MNCs) for development and commercialization, with a primary focus on the Greater China market and secondary markets in South-east Asia. Edding aims to provide rapid development capabilities supported by an extensive commercial network that includes 300 regional distributors, over 16,000 hospitals, and 13,000 pharmacies.
Key Products and Licensing Partnerships
Edding’s key on-market products include a range of in-licensed pharmaceuticals. These are the antibiotics Zinacef (cefuroxime) and Ceclor (cefaclor), licensed from Eli Lilly & Co., the asthma treatment fluticasone, from GlaxoSmithKline, and the statin-type drug Vascepa (vancomycin), licensed from Amarin Corp. These partnerships highlight Edding’s strategy of leveraging established pharmaceuticals to serve its target markets.-Fineline Info & Tech
